Rani Therapeutics Holdings Inc RANI

Healthcare Biotechnology

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

NDAQ:RANI - Post by User

Rani Therapeutics Holdings Inc

<< Previous

Bullboard Posts

Next >>

(44)
•••

Post by mlmack66on Oct 16, 2024 4:52am

117 Views

Post# 36267562

Crazy two days for RANI, huge volume

From $2.00 to $3.75 on the Oppenheimer upgrade and $12 - $17 price targets. Then back down to $2.12 on the $10 M Registered Direct Offering. Risk / Reward looks exceptional at $2.12 as their technology goes through various Trials and approvals.

<< Previous

Bullboard Posts

Next >>

Constellation Software Q3 2025 earnings: Revenue up 16 per cent